<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Articles SYSTEM "HBI_DTD">
<Articles><Article><Journal><PublisherName></PublisherName><JournalTitle>DARU Journal of Pharmaceutical Sciences</JournalTitle><Volume>10</Volume><Issue>2</Issue></Journal><ArticleTitle>Evaluation of tumor targeting with radiolabeled F(ab)2 fragment of a humanized monoclonal antibody</ArticleTitle><FirstPage>49</FirstPage><LastPage>53</LastPage><AuthorList><Author><FirstName></FirstName><LastName>"Babaei MH</LastName></Author><Author><FirstName></FirstName><LastName>Farshid Far R</LastName></Author><Author><FirstName></FirstName><LastName>Najafi R "</LastName></Author></AuthorList><History><PubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>06</Day></PubDate></History><Abstract>Humanized monoclonal antibody U36 and its F(ab')2 fragment, radio labeled with 125I, were tested for tumor localization in nude mice bearing a squamous cell carcinoma xenograft line derived from a head and neck carcinoma. Monoclonal antibody IgG or F(ab')2 fragment were injected in parallel and at days 1, 2 and 3, mice were dissected for determination of isotope biodistribution. IgG as well as F(ab')2 showed highly specific localization in tumor tissue. The mean tumor uptake (n=3) is expressed as the percentage of the injected dose per gram of tumor tissue (%ID/g). %ID/g of IgG was 11.7% at day 1 and decreased to 10.9% at day 3 whereas %ID/g of F(ab')2 was 2.9% at day 1 and decreased on following days. Tumor to blood ratios (T/B) at day 1 were 0.86 for IgG and 1.32 for F(ab')2 and reached a maximum at day 3 with values of 4.41 and 1.84 respectively. These findings suggest that the superior tumor to non-tumor ratios in the day of 1 render the F(ab')2 fragment more qualified for specific targeting radioisotopes to tumor xenografts in this exprimental setting.</Abstract><web_url>https://daru.tums.ac.ir/index.php/daru/article/view/139</web_url><pdf_url>https://daru.tums.ac.ir/index.php/daru/article/download/139/139</pdf_url></Article></Articles>
